The carE gene of streptomyces thermotolerans has been isolated and used to construct recombinant dna expression vectors. The carE gene encodes 4"-O-isovaleryl acylase activity important in the biosynthesis of a number of useful antibiotics. The carE gene can be used not only to construct recombinant cells with an increased ability to produce the acylase enzyme but also to construct recombinant cells with the ability to produce novel antibiotic compounds.
|
1. A method for increasing the amount of 4"-O-isovalerylacylase enzyme in an organism that comprises (1) transforming said organism with a recombinant dna vector that codes for expression of the streptomyces carE gene product; and (2) culturing said organism transformed in step (1) under conditions that allow for gene expression.
8. The constructed dna compound of
9. The constructed dna compound of
10. The dna constructed compound of
26. The host cell of
27. The host cell of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The present invention relates to a novel gene, designated carE, that encodes a 4"-O-isovaleryl acylase enzyme, methods for using the carE gene, recombinant DNA cloning vectors that encode the acylase enzyme, transformants containing the vectors, and the enzyme produced by the transformants. Streptomyces thermotolerans produces carbomycin, a macrolide antibiotic consisting of a 16-member cyclic lactone and two sugar residues, mycarose and mycaminose. The antibiotic activity of carbomycin, like that of other macrolides, is due to inhibition of protein synthesis by a mechanism that involves the binding of carbomycin to the ribosome. The biosynthesis of carbomycin involves the attachment of an isovaleryl group (derived from isovaleryl coenzyme A) at the 4"-OH position of the mycarose residue mediated by an acylase enzyme. The carE gene encodes a 4"-O-isovaleryl acylase activity.
The present invention provides expression vectors that encode the isovaleryl acylase useful in Streptomyces and many other host cells. The development and exploitation of recombinant DNA technology in Streptomyces has been driven by the desire to improve the antibiotic-producing ability of this industrially important organism, not only to increase antibiotic yield, but also to produce novel antibiotics. This development has been somewhat retarded by the low number of antibiotic biosynthetic genes presently available for use in modifying Streptomyces by recombinant DNA technology. The present invention is useful and especially important in that it expands the number of antibiotic biosynthetic genes suitable for such use.
The vectors of the present invention are particularly useful, because the vectors can be introduced into and selected for in a variety of Streptomyces cells. Streptomyces provides over half of the clinically important antibiotics and thus is a commercially significant group. The present invention provides new and useful vectors and methods not only for this industrially important group but also for other antibiotic-producing organisms and allows for increasing the yield of carbomycin in fermentations and also for producing new antibiotics and antibiotic derivatives.
For purposes of the present invention, as disclosed and claimed herein, the following terms are defined below.
AmR -- the apramycin resistance-conferring gene.
Antibiotic -- a substance produced by a microorganism which, either naturally or with limited modification, will inhibit the growth of or kill another microorganism or eukaryotic cell.
Antibiotic Biosynthetic Gene -- a DNA segment that encodes one or more activities that can mediate the biochemical process of converting primary metabolites into antibiotics.
Antibiotic Biosynthetic Pathway -- an entire set of antibiotic biosynthetic genes minimally required for the process of converting primary metabolites into antibiotics.
Antibiotic-Producing Organism -- any organism, including, but not limited to, Actinoplanes, Actinomadura, Bacillus, Cephalosporium, Micromonospora, Penicillium, Nocardia, and Streptomyces, which either produces an antibiotic or contains genes which, if expressed, would produce an antibiotic.
Antibiotic Resistance-Conferring Gene -- a DNA segment that encodes an enzymatic or other activity that confers resistance to an antibiotic.
ApR -- the ampicillin resistance-conferring gene.
Bifunctional Cloning Shuttle Vector -- a recombinant DNA cloning vector that can replicate and/or integrate into organisms of two different taxa.
carA -- a carbomycin resistance-conferring gene of type A.
carB -- a carbomycin resistance-conferring gene of type B.
carG -- a DNA sequence that comprises one or more genes that encode the activities required to form the 16-member cyclic lactone of carbomycin.
carE -- a DNA sequence that can be isolated from Streptomyces thermotolerans that encodes a 4"-O-isovaleryl acylase activity.
Cloning -- the process of incorporating a segment of DNA into a recombinant DNA cloning vector and transforming a host cell with the recombinant DNA.
cos -- the lambda cohesive end sequence.
Cosmid -- a recombinant DNA cloning vector which not only can replicate in a host cell in the same manner as a plasmid but also can be packaged into phage heads.
Gene -- a DNA sequence that comprises a promoter and coding sequence positioned so that the promoter drives transcription of the coding sequence.
Genetic Library -- a set of recombinant DNA cloning vectors into which segments of DNA, comprising substantially all of the DNA of a particular organism, have been cloned.
Hybridization -- the process of annealing two single-stranded DNA molecules to form a double-stranded DNA molecule, which may or may not be completely basepaired.
NmR -- the neomycin resistance-conferring gene.
ori -- a plasmid origin of replication.
Phasmid--a recombinant DNA vector that may act as a phage or as a plasmid.
Recombinant DNA Cloning Vector -- any autonomously replicating or integrating agent, including, but not limited to, plasmids, comprising a DNA molecule to which one or more additional DNA molecules can be or have been added.
Restriction Fragment -- any linear DNA molecule generated by the action of one or more restriction enzymes.
rRNA -- ribosomal ribonucleic acid.
Sensitive Host Cell -- a host cell that cannot grow in the presence of a given antibiotic without a DNA segment that confers resistance thereto.
TcR -- the tetracycline-resistant phenotype or gene conferring same.
Transductant -- a recipient host cell that has undergone transformation by recombinant phage infection.
Transformant -- a recipient host cell that has undergone transformation.
Transformation -- the introduction of DNA into a recipient host cell that changes the genotype and results in a change in the recipient cell.
tsrR -- the thiostrepton-resistant phenotype or gene conferring same.
The figures described below are drawn to scale; however, observed restriction fragment size may vary somewhat from calculated size based on map distances. For some restriction enzymes, such as MboI, only certain cut sites are shown for convenience.
FIG. 1 is a restriction site and function map of plasmid pOJ171.
FIG. 2 is a restriction site and function map of plasmid pOJ160.
FIG. 3 is a restriction site and function map of plasmid pOJ313.
FIG. 4 is a restriction site and function map of plasmid pOJ159.
FIG. 5 is a restriction site and function map of plasmid pOJ230.
FIG. 6 is a restriction site and function map of plasmid pOJ235.
FIG. 7 is a restriction site and function map of plasmid pCZR111.
The present invention relates to a novel gene, designated carE, that encodes a 4"-O-isovaleryl acylase activity. Recombinant DNA expression vectors that encode the acylase can be used to increase antibiotic yield and to produce new antibiotics. The coding sequence of the carE gene is useful in a method for increasing the 4"-O-isovaleryl acylase activity in an organism. The method comprises transforming the organism with a recombinant DNA vector that codes for expression of the carE gene product and culturing the transformed cell under conditions suitable for gene expression.
The carE gene was isolated from a carbomycin-producing strain of Streptomyces thermotolerans, available from the American Type Culture Collection, Rockville, Md. 20852 under the accession number ATCC 11416. Thus, genomic DNA of S. thermotolerans was partially digested with restriction enzyme MboI, and the resulting DNA was inserted into HpaI-BamHI-digested cosmid pKC462A (available from the Agricultural Research Service, Northern Regional Research Center, Peoria, Ill. 61604, under the accession number NRRL B-15973) to yield a number of carE-containing plasmids, including plasmid pOJ171. Plasmid pOJ171 (FIG. 1) can be isolated from E. coli K12 SF8/pOJ171 (NRRL B-18169) as described in Example 1. The carE gene can be isolated from plasmid pOJ171 on an ∼3.8 kb EcoRI restriction fragment.
The carE gene can also be isolated from plasmid pOJ159, which contains a carbomycin resistance-conferring gene, designated carB, that is useful as a genetic marker in many organisms. Plasmid pOJ159 (FIG. 4) can be isolated from Streptomyces griseofuscus C581/pOJ159 (NRRL 18090) as described in Example 2. Plasmid pOJ159 was constructed by partially digesting genomic DNA of Streptomyces thermotolerans with restriction enzyme MboI, inserting the resulting DNA into BglII-digested plasmid pIJ702 (ATCC 39155), and identifying carbomycin-resistant Streptomyces transformants.
However, plasmid pOJ159 also contains a carE gene of the present invention. Because the carE gene was isolated from Streptomyces thermotolerans, the carE gene drives expression of acylase activity in S. thermotolerans and other host cells in which the promoter of the carE gene functions. Those skilled in the art will recognize that the intact carE gene of S. thermotolerans can be used to generate 4"-O-isovaleryl acylase activity in a variety of host cells, especially Streptomyces of any species.
The sequence of the carE gene is depicted below, beginning with the 5' end upstream of the coding sequence. This 5' noncoding sequence contains the promoter of the carE gene, another important aspect of the present invention. Only the sequence of the coding strand of the carE gene is depicted; the sequence of the non-coding strand can be obtained using the well-known rules of base-pairing: A pairs with T, and C pairs with G. The amino acid residue sequence of the carE gene product is also depicted below, beginning with the amino-terminal end; each amino acid residue is located below the DNA encoding that residue. Both the DNA and amino acid residue sequences are numbered to facilitate an understanding of the invention. ##STR1## In the sequence above, A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, T is thymidyl, Ala is an alanine, Arg is an arginine, Asn is an asparagine, Asp is an aspartic acid, Cys is a cysteine, Gln is a glutamine, Glu is a glutamic acid, Gly is a glycine, His is a histidine, Ile is an isoleucine, Leu is a leucine, Lys is a lysine, Met is a methionine, Phe is a phenylalanine, Pro is a proline, Ser is a serine, Thr is a threonine, Trp is a tryptophan, Tyr is a tyrosine, and Val is a valine.
A variety of vectors of the invention can be readily constructed using either plasmid pOJ171 or pOJ159 as starting material. Vectors that comprise the intact carE gene are especially preferred for use in Streptomyces. For example, the ∼3.8 kb, carE gene-containing, EcoRI restriction fragment of plasmid pOJ171 was isolated and inserted into EcoRI-digested plasmid pOJ160 (FIG. 2 and NRRL B-18088) to yield plasmids pOJ313 (FIG. 3) and pOJ313A, which differ only with respect to the orientation of the ∼3.8 kb EcoRI restriction fragment. The construction protocol for plasmids pOJ313 and pOJ313A is given in Example 3.
Plasmid pOJ230 (FIG. 5) of the invention was derived from plasmid pOJ159 by ligating the ∼2.4 kb, carE gene-containing BamHI restriction fragment of plasmid pOJ159 to BamHI-digested plasmid pOJ160, as described in Example 4. Because this fragment could insert in either of two orientations, the ligation produced two plasmids, designated pOJ230 and pOJ231, that differ only with respect to the orientation of the ∼2.4 kb, carE-containing, BamHI restriction fragment.
Vectors of the present invention that contain the intact carE gene are preferred for use in increasing the 4"-O-isovaleryl transferase activity in organisms that biosynthesize carbomycin or other macrolide antibiotics. Consequently, Streptomyces, especially species that produce an antibiotic that contains a mycarose or related sugar, are preferred host cells for vectors of the invention that contain the intact carE gene. Of course, the carE gene can be reconstructed using recombinant DNA techniques for purposes of producing the carE gene product in any host cell.
Illustrative vectors of the present invention were introduced into Streptomyces ambofaciens for purposes of exemplifying the use of the intact carE gene to increase the 4"-O-isovaleryl acylase activity of an organism. S. ambofaciens produces spiramycin and a variety of other spiramycin-related compounds that contain a mycarose residue with a 4"-OH group. S. ambofaciens does not naturally produce a 4"-O-isovaleryl acylase activity. Plasmids pOJ159, pOJ171, pOJ230, pOJ231, and pOJ313 have been used to transform S. ambofaciens, as described in Example 5. The resulting transformants produce isovaleryl spiramycin due to the presence of the acylase-encoding recombinant DNA vector.
Similarly, when plasmids pOJ159 and pOJ313 were used to transform Streptomyces lividans TK23 (NRRL 15826), the resulting transformants could not only grow in the presence of higher levels of spiramycin (due to the carB gene product) but also converted the spiramycin to isovaleryl spiramycin. A transformation protocol for S. lividans is set forth in Example 6.
Vectors of the invention are thus generally useful to acylate the mycarose residues of macrolide antibiotics such as spiramycin and carbomycin. Streptomyces fradiae produces tylosin, another macrolide antibiotic that contains a mycarose residue. U.S. Pat. No. 4,092,473 describes a 4" acylation of the mycarose residue of tylosin to produce isovaleryl tylosin, an important antibiotic. U.S. Pat. No. 4,656,258 describes the production of isovaleryl macrocin. The 4"-OH group of mycarose is not acylated in tylosin or its intermediates, but recombinant DNA vectors of the present invention can be used to transform a tylosin-producing cell into a cell that produces 4"-acylated tylosin and 4"-acylated tylosin intermediates.
The intact carE gene isolated from Streptomyces thermotolerans expressed well in S. ambofaciens and S. lividans. Yet even if the original carE gene failed to express in a given organism, such as E. coli, because, for example, the Streptomyces promoter of the carE failed to function in that organism, the carE coding sequence of the present invention could be ligated to a DNA fragment containing an appropriate promoter, ribosome-binding site or other regulatory element to achieve expression of the carE gene in the host of choice. This technique is illustrated in the construction of an E. coli expression vector of the invention, designated pOJ235 and more fully described below.
Plasmids pOJ159, pOJ171, pOJ230, pOJ231, pOJ313, and pOJ313A contain the intact carE gene: (1) a promoter that directs transcription of the protein-coding sequence; (2) a sequence that, when transcribed into mRNA, directs translation of the transcript; (3) a protein-coding sequence; and (4) a transcription terminator. Each of these elements is independently useful and can, through the techniques of recombinant DNA technology, be used to form recombinant genes of great variety. The DNA sequence of the carE gene, provided above, reveals the location of the carE coding sequence and thus allows one to position other promoters, for example, the trp, lpp, and lac promoters of E. coli, the hybrid tac promoter, the λpL promoter, and the veg promoter of Bacillus, in reading phase with the carE coding sequence. By choosing the proper promoter, one can construct vectors that drive expression of the carE gene product in any host cell. The promoter of the carE gene of Streptomyces thermotolernas is useful in its own right. The promoter and other regulatory elements of the carE gene can be linked to any coding sequence to produce useful recombinant genes. Thus, the individual elements of the carE gene, both the promoter and coding sequence, comprise important components of the present invention.
The promoter of the carE gene is contained within nucleotides 1 to 580 in the carE gene sequence depicted above. This sequence also contains the sequence 5'-CCGTCCGCCG-3' (see sequence around nucleotide number 570), which is present in a number of antibiotic biosynthetic and antibiotic resistance-conferring genes. The sequence 5'-CCGTCCGCCG-3' and closely related sequences, such as 5'-CCGTCCCGCCG-3', are believed to be important in the regulation of such genes and thus can be used as a probe to detect antibiotic biosynthetic and antibiotic resistance-conferring genes.
Those skilled in the art will recognize that the carE sequence deposited under accession number NRRL B-18169 and NRRL 18090 can be used to prepare DNA probes for use in obtaining other biosynthetic gene-containing DNA segments, especially segments encoding macrolide biosynthetic genes. In addition, due to the diversity of Streptomyces thermotolerans strains both in nature and also in the laboratory, there will be a variety of allelic variants of the carE gene that can be readily isolated given the carE gene-containing compounds of this invention. These allelic variants, which encode gene products with an amino acid residue sequence that differs from that of the carE gene product, are functionally equivalent to the carE gene of the present invention.
For example, those skilled in the art will recognize that the carE gene from the improved bioconverting strain of Streptomyces thermotolerans NRRL 15270 described in U.S. Pat. No. 4,522,919 can be isolated on an ∼2.4 kb BamHI restriction fragment as follows. BamHI restriction fragments are generated from genomic DNA isolated from the NRRL 15270 strain and inserted into BamHI-digested plasmid pOJ160. This procedure yields a genomic library of S. thermotolerans NRRL 15270, and this library can be transformed into E. coli and the resulting transformants probed by colony hybridization using the ∼2.4 kb, carE-containing, BamHI restriction fragment of, for example, plasmid pOJ230 as a hybridization probe. Plasmid DNA isolated from colonies that hybridize in the procedure contains the ∼2.4 kb, carE-containing, BamHI restriction fragment of S. thermotolerans NRRL 15270. The carE gene of S. thermotolerans NRRL 15270 and the coding sequence of that gene are important compounds of the present invention, because the carE gene product of the NRRL 15270 strain is believed to have a different substrate specificity than the carE gene product of wild-type S. thermotolerans. Analogous procedures can be used to generate carE-containing DNA from any organism that contains carE-encoding DNA.
A variety of known Streptomyces replicons can be used in conjunction with the carE gene to construct expression vectors of the present invention. Table I is an illustrative, but not comprehensive, listing of Streptomyces plasmids from which Streptomyces replicons can be obtained. Those skilled in the art recognize that, so long as the replicon function is not disrupted, all or part of the plasmids can be used to construct vectors that contain the carE gene of the present invention. The plasmid-containing host and depository accession number are also listed in Table I.
| TABLE I |
| ______________________________________ |
| Streptomyces Plasmids |
| Accession |
| Plasmid Host Number |
| ______________________________________ |
| SCP2 Streptomyces coelicolor A3(2) |
| NRRL 15042 |
| SCP2* Streptomyces coelicolor M110 |
| NRRL 15041 |
| pEL7 Streptomyces ambofaciens/pEL7 |
| NRRL 12523 |
| pUC6 Streptomyces espinosus |
| NRRL 11439 |
| pUC3 Streptomyces 3022A NRRL 11441 |
| SLP1 Streptomyces lividans |
| NCIB* 11417 |
| pNM100 Streptomyces virginiae |
| NRRL 15156 |
| pEL103 Streptomyces granuloruber |
| NRRL 12549 |
| A399 12.13/pEL103 |
| pIJ702 Streptomyces lividans |
| ATCC 39155 |
| ______________________________________ |
| *National Collection of Industrial Bacteria (NCIB), Torry Research |
| Station, Post Office Box 31, 135 Abbey Road, Aberdeen AB98DG, Scotland, |
| United Kingdom. |
Restriction fragments used to construct vectors illustrative of the present invention can be conventionally modified to facilitate ligation. For example, molecular linkers can be provided to a particular carE biosynthetic gene-containing restriction fragment or to DNA comprising vector replication or integration functions. Thus, specific sites for subsequent ligation can be conveniently constructed. In addition, the various carE biosynthetic gene-containing restriction fragments or sequences that provide for replication or chromosomal integration of a given vector can be modified by adding, eliminating, or substituting certain nucleotides to alter characteristics and to provide a variety of restriction sites for ligation of DNA. Those skilled in the art understand nucleotide chemistry and the genetic code and thus which nucleotides are interchangeable and which DNA modifications are desirable for a specific purpose. Thus, a myriad of DNA sequences that encode the carE gene product can be constructed. It is also noteworthy that a given carE biosynthetic gene-containing restriction fragment is not limited to a particular position on a cloning vector, as long as critical, vector-controlled functions are not disrupted. Those skilled in the art understand or can readily determine which sites on a vector are advantageous for the ligation or insertion of a particular carE gene-containing restriction fragment.
Of course, the carE gene or coding sequence can be used to construct vectors other than plasmids. Phage φC31 is a well-known Streptomyces phage that is an excellent source of starting material for constructing integrative carE gene-containing vectors that further exemplify the present invention. A derivative of phage φC31, phasmid pKC331, is especially preferred for constructing such integrating vectors and can be obtained from E. coli K12 BE447/pKC331 (NRRL B-15828). φC31-type phages are integrative vectors and can be readily modified to incorporate the carE gene and thus confer 4"-O-isovaleryl acylase activity to Streptomyces. Even plasmids that contain a replicon that provides for extrachromosomal maintenance of the plasmid sometimes integrate into the genome of the host cell, usually with concomitant deletion of the replicon sequences. The present invention thus is not limited by the type of vector used to introduce the carE gene or coding sequence into the target host cell nor by the location of the carE gene or coding sequence once introduction has occurred.
Vectors of the present invention preferred for Streptomyces contain a Streptomyces replicon and a carE gene-containing restriction fragment. Because amplification and manipulation of plasmids is done faster and more efficiently in E. coli than in Streptomyces, it is convenient to add DNA sequences that also allow for replication in E. coli. Thus, the addition of functional replicon-containing and antibiotic resistance-conferring restriction fragments from E. coli plasmids such as, for example, pUC8, pUC18, pUC19, pBR322, pACYC184, pBR325, pBR328, and the like is highly advantageous and adds to the general utility of the present illustrative vectors.
The present invention provides 4"-O-isovaleryl acylase expression vectors that not only contain E. coli replicons but also contain recombinant E. coli carE genes. The recombinant E. coli carE gene contains a promoter that functions in E. coli positioned to drive expression of the carE gene product. Illustrative plasmid pOJ235 (FIG. 6) of the invention can be constructed as described in Example 7. Plasmid pOJ235 drives expression of the carE gene product in E. coli and contains the carE coding sequence under the control of the λpL promoter, itself regulated by a temperature-sensitive cI857 gene product also encoded on the plasmid.
Those skilled in the art recognize that the carE gene, its coding sequence, and its promoter can be individually combined with a variety of other DNA compounds to create useful 4"-O-isovaleryl acylase and other expression vectors of the invention. For instance, Streptomyces thermotolerans contains two carbomycin resistance-conferring genes, designated carA and carB. These two carbomycin resistance genes may act in concert to cause high-level resistance in Streptomyces thermotolerans. The present invention also provides vectors that contain the carE gene and either or both of the carA and carB genes. Plasmid pOJ171, for example, comprises both the carE and carB genes. Plasmid pOJ171 also encodes carG, which encodes an activity involved in the biosynthesis of the lactone ring of carbomycin in S. thermotolerans.
The cloning vectors and transformants of the present invention provide for the cloning of genes to improve and alter yields of various products that are currently produced in Streptomyces and related cells. Examples of such products include, but are not limited to, carbomycin, tylosin, erythromycin, and the like. The present invention also provides selectable vectors that are useful for cloning, characterizing, and reconstructing a variety of useful DNA sequences.
Streptomyces transformants of the invention can be cultured in a number of ways using any of several different media. Preferred carbohydrate sources in a culture medium include, for example, molasses, glucose, dextrin, and glycerol. Nitrogen sources include, for example, soy flour, amino acid mixtures, and peptones. Nutrient inorganic salts are also incorporated and include the customary salts capable of yielding sodium, potassium, ammonium, calcium, phosphate, chloride, sulfate, and like ions. As is necessary for the growth and development of other microorganisms, essential trace elements are also added. Such trace elements are commonly supplied as impurities incidental to the addition of other constituents of the medium.
Streptomyces is grown under aerobic culture conditions over a relatively wide pH range of about 5 to 9 at temperatures ranging from about 15° to 40°C For plasmid stability and maintenance, it is desirable to start with a culture medium at a pH of about 7.2 and maintain a culture temperature of about 30°C
The following examples further illustrate and describe the invention disclosed herein. The invention is not limited in scope by reason of any of the following Examples; sources of reagents or equipment are provided merely for convenience and in no way limit the invention. Both an explanation of and the actual procedures for constructing the invention are described where appropriate.
PAC Isolation of Plasmid pOJ171Plasmid pOJ171 can be obtained from the Northern Regional Research Center in E. coli K12 SF8 under the accession number NRRL B-18169. The lyophils of E. coli K12 SF8/pOJ171 are plated onto L-agar plates containing 200 μg/ml apramycin to obtain a single colony isolate of the strain. This colony is used to inoculate about 500 ml of L broth containing 200 μg/ml apramycin, and the resulting culture is incubated at 37° C. with aeration until the cells reach stationary phase.
Plasmid DNA was obtained from the cells to use in construction of plasmid pOJ313 in accordance with the following procedure, which is adapted from Maniatis et al., 1982, Molecular Cloning (Cold Spring Harbor Laboratory). This same procedure was used, but on a smaller scale and with the ultracentrifugation steps replaced with phenol followed by chloroform extractions, to prepare the plasmid DNA used to identify the E. coli K12 RR1ΔM15/pOJ313 transformants.
About 500 ml of stationary-phase E. coli/pOJ171 cells are harvested by centrifugation at 4000Xg for 10 minutes at 4°C, and the supernatant is discarded. The cell pellet is washed in 100 ml of ice-cold STE buffer (0.1 M NaCl; 10 mM Tris-HCl, pH 7.8; and 1 mM EDTA). After the cell pellet is washed, the pellet is resuspended in 10 ml of Solution 1 (50 mM glucose; 25 mM Tris-HCl, pH=8.0; and 10 mM EDTA) that contains 1 mg/ml lysozyme and is left at room temperature for 10 minutes. Twenty ml of Solution 2 (0.2 N NaOH and 1% SDS) are then added to the lysozyme-treated cells, and the solution is gently mixed by inversion. The mixture is incubated on ice for 10 minutes.
Fifteen ml of ice-cold, 3 M sodium acetate, pH=4.8, are added to the lysed-cell mixture, and the solution is mixed by inversion. The solution is incubated on ice for 60 minutes. The 3 M sodium acetate solution is prepared by mixing equal volumes of 3 M acetic acid and 3 M sodium acetate.
The lysed cell mixture is centrifuged in an ultracentrifuge at 20,000 rpm for 20 minutes at 4°C About 36 ml of supernatant are recovered, and 2.5 volumes of ethanol are added, mixed, and the resulting solution left on ice for 15 minutes. The plasmid DNA is collected by centrifugation at 12,000Xg for 30 minutes at room temperature. The supernatant is discarded, and the DNA pellet is washed with 70% ethanol at room temperature. The ethanol wash is decanted, and the pellet is dried in a vacuum desiccator. The pellet is then resuspended in 8 ml of TE buffer (10 mM Tris-HCl, pH=8.0, and 1 mM EDTA).
Eight grams of CsCl are added to the DNA solution. About 0.8 ml of a 10 mg/ml solution of ethidium bromide in water are added for each 10 ml of CsCl-DNA solution. The final density of the solution is about 0.761 g/ml, and the ethidium bromide concentration is about 800 μg/ml. The solution is transferred to an ultracentrifuge tube, filled to the top with TE buffer containing 0.761 g of CsCl per ml, sealed, and centrifuged at 45,000 rpm for 24 hours at 20°C After centrifugation, two bands of DNA are visible in ordinary light and become even more prominent in UV light. The cap is removed from the tube, and the lower DNA band is recovered using a syringe with a #21 hypodermic needle inserted through the side of the centrifuge tube.
The ethidium bromide is removed from the solution of plasmid DNA by several extractions with water-saturated 1-butanol, and the CsCl is removed by dialysis against TE buffer. After extractions with buffered phenol and then chloroform, the DNA is precipitated, washed with 70% ethanol, and dried. About 0.5 mg of plasmid pOJ171 DNA can be obtained by this procedure. A restriction site and function map of plasmid pOJ171 is presented in FIG. 1 of the accompanying drawings.
PAC Isolation of Plasmid pOJ159About 108 spores of Streptomyces griseofuscus C581/pOJ159 (NRRL 18090) are inoculated into 10 ml of Trypticase Soy Broth (TSB is made at 30 g/L and is obtained from Baltimore Biological Laboratories (BBL), P.O. Box 243, Cockeysville, Md. 21031) containing 25 μg/ml thiostrepton and grown at 29°C until the culture is in early stationary phase. The culture was then homogenized, and 5 ml of the homogenized culture were used to inoculate 100 ml of TSB also containing thiostrepton. The 100 ml of culture were incubated at 29°C until the Streptomyces griseofuscus C581/pOJ159 cells reached stationary phase.
The cells were collected and washed once with a 10.3% sucrose solution. The cells were then suspended in 24 ml of 10.3% sucrose, and 6 ml of 5X lysozyme solution (125 mM Tris-HCl, pH=8; 125 mM Na2 EDTA, pH=8; 10 mg/ml lysozyme; and 10.3% sucrose) were added. The solution was mixed and then incubated at 30°C for 30-60 minutes, and then, about 18 ml of a solution that was 0.3 M NaOH, 1% SDS, and prewarmed to 50°C were added, mixed and the resulting mixture incubated at 80°C for 10 minutes. The mixture was then cooled to room temperature, and 12 ml of a solution made by mixing 500 g phenol and 500 g CHCl3 in 200 ml H2 O were added and mixed well with the cell-extract. The phases were separated by centrifugation at 6000-8000 rpm for 10 minutes; approximately 45 ml of the resulting upper phase were transferred to a clean bottle.
Next, 4.5 ml of 3 M NaOAc and 50 ml of isopropanol were added to the supernatant, and the solution was mixed and left at room temperature for 30 minutes. The solution was then centrifuged (8000 rpm for 30 minutes) and the resulting supernatant discarded. The pellet was resuspended in 10 ml of TE buffer (10 mM Tris-HCl, pH=8, and 1 mM EDTA) containing 9.5 g of CsCl. About 1 ml of a 5 mg/ml solution of ethidium bromide was added to the solution to bring the final volume to 12.5 ml. The solution was then centrifuged at 52,000 rpm for 48 hours at 20°C in a fixed-angle ultracentrifuge rotor. The fraction containing the plasmid band was extracted 5 times with isopropanol saturated with 20X SSC (0.3 M NaCl and 0.3 M NaCitrate) to remove the ethidium bromide. After the extractions, the sample was dialyzed against 1000 volumes of H2 O and then against 1500 volumes of TE buffer. The procedure yields about 100 μg of plasmid pOJ159 DNA at a concentration of ∼0.2 μg/μl and is stored at 4°C A restriction site and function map of plasmid pOJ159 is presented in FIG. 4 of the accompanying drawings.
PAC Construction of Plasmid pOJ313 and pOJ313APlasmid pOJ160 can be obtained from the Northern Regional Research Center in E. coli K12 JM109 under the accession number NRRL B-18088. The lyophils of E. coli K12 JM109/pOJ160 are plated onto L-agar plates containing 200 μg/ml apramycin to obtain a single colony isolate of the strain. This colony is used to inoculate about 500 ml of L broth containing 200 μg/ml apramycin, and the resulting culture is incubated at 37° C. with aeration until the cells reach stationary phase.
Plasmid DNA was obtained from the cells to use in construction of plasmid pOJ313 in accordance with the procedure set forth in Example 1, above. About 0.5 mg of plasmid pOJ160 DNA can be obtained by this procedure. A restriction site and function map of plasmid pOJ160 is presented in FIG. 2 of the accompanying drawings.
About 10 μg (10 μl) of plasmid pOJ160 DNA were added to 2 μl of 10X EcoRI buffer (1.0 M Tris-HCl, pH=7.5; 0.5 M NaCl; 50 mM MgCl2 ; and 1 mg/ml BSA), 6 μl of H2 O, and 2 μl (∼30 units; unit definitions herein correspond to those of New England Biolabs, 32 Tozer Road, Beverly, Mass. 01915-9990, unless otherwise indicated) of restriction enzyme EcoRI. The resulting reaction was incubated at 37°C for two hours. The EcoRI-digested plasmid pOJ160 DNA was collected by adjusting the sodium acetate (NaOAc) concentration of the reaction mixture to 0.30 M, adding 2.5 volumes of ethanol, chilling the reaction mixture to -70°C, and centrifuging to pellet the precipitated DNA. The pellet of EcoRI-digested plasmid pOJ160 DNA was resuspended in 400 μl of TE buffer (10 mM Tris-HCl, pH=8.0, and 1 mM EDTA). About 1 μl (0.1 unit) of bacterial alkaline phosphatase (International Biotechnology, Inc., P.O. Box 1565, New Haven, Conn. 06506) was added to the DNA solution, and the reaction was incubated at 65°C for 1 hour. The reaction mixture was extracted with 400 μl of a 1:1 solution of phenol:chloroform and then extracted with 400 μl of chloroform. The EcoRI-digested, dephosphorylated plasmid pOJ160 DNA was collected by ethanol precipitation and centrifugation as described above, and the DNA pellet was resuspended in 10 μl of TE buffer.
About 10 μg of plasmid pOJ171 in 100 μl of TE buffer were added to 13 μl of 10X EcoRI buffer, 13 μl of H2 O, and 4 μl (∼60 units) of restriction enzyme EcoRI. The resulting reaction was incubated at 37°C for 2 hours. The reaction mixture was extracted, and the DNA was collected as described above. The DNA pellet was redissolved, loaded onto an agarose gel, and about ∼0.5 μg of the desired ∼3.8 kb, carE-containing, EcoRI restriction fragment of plasmid pOJ171 were purified from the gel and prepared for ligation.
The EcoRI-digested, dephosphorylated plasmid pOJ160 DNA (1 μl) was added to 10 μl (∼0.5 μg) of the ∼3.8 kb EcoRI restriction fragment, 2 μl of 10X ligase buffer (660 mM Tris-HCl, pH=8; 66 mM MgCl2 ; 10 mM dithiothreitol (DTT); and 10 mM ATP), and 6 μl of H2 O. About 1 μl (∼100 units) of T4 DNA ligase was added to the solution of DNA, and the resulting reaction was incubated at 15°C overnight (∼16 hours). The ligated DNA contained the desired plasmid pOJ313; a restriction site and function map of plasmid pOJ313 is presented in FIG. 3 of the accompanying drawings. Because the ∼3.8 kb, carE gene-containing EcoRI restriction fragment of plasmid pOJ171 could insert into plasmid pOJ160 in either of two orientations, the ligation also produced plasmid pOJ313A, which differs from plasmid pOJ313 only with respect to the orientation of the carE gene-containing, EcoRI restriction fragment.
The EcoRI site on plasmid pOJ160 resides within a polylinker that itself forms part of the DNA sequence encoding the lacZ α-fragment. Expression of the lacZ α-fragment in an E. coli ΔM15 strain, such as E. coli K12 RR1ΔM15 (NRRL B-15440), restores the strain's ability to produce a functional β-galactosidase enzyme. Thus, plasmid pOJ160 can restore β-galactosidase activity to the E. coli K12 RR1ΔM15 strain. However, insertion of DNA into a restriction site of the polylinker linker on plasmid pOJ160, as occurs in the construction of plasmid pOJ313, disrupts the lacZ α-fragment coding sequence and concomitantly destroys the ability of the plasmid pOJ160 derivative to complement the ΔM15 mutation. β-galactosidase can hydrodyze X-Gal, which is 5-bromo-4- chloro-3-indolyl-β-D-galactopyranoside, a colorless compound, to an indigo-colored product and thus allows for a convenient screening method for discriminating between transformants containing starting plasmid pOJ160 and those containing a plasmid pOJ160 derivative, such as plasmid pOJ313.
To prepare E. coli K12 RR1ΔM15 cells that are competent for transformation, the lyophils of E. coli K12 RR1ΔM15 obtained from the NRRL are reconstituted to isolate single colonies. One single-colony isolate of RR1ΔM15 was inoculated into 10 ml of L broth, and the culture was incubated at 37°C overnight with aeration. The overnight culture was used to inoculate 200 ml of L broth to yield a culture with an O.D.600 of about 0.1. The culture was incubated at 37°C with aeration until the O.D.600 was about 0.6. The culture was collected by centrifugation at 4000Xg for 10 minutes at 4°C, resuspended in 100 ml of cold 50 mM CaCl2, and incubated on ice for 15 to 30 minutes.
The cells were again collected by centrifugation and resuspended in 10 ml of cold 50 mM CaCl2 containing 20% glycerol. A 200 μl aliquot of the cells was added to the ligated DNA prepared above. The cell-DNA mixture was incubated on ice for one hour, centrifuged, and the cell pellet was resuspended into 0.5 ml of L broth in a 1.5 ml tube and incubated with aeration at 37°C for one-half hour.
Aliquots of the transformation mixture were plated on L-agar plates containing 200 μg apramycin/ml, 40 μg X-gal/ml, and 40 μg IPTG/ml. IPTG serves to derepress the lac promoter present on plasmid pOJ160. The plates were incubated at 37°C overnight. Colonies that contain a plasmid without an insert, such as E. coli K12 RR1ΔM15/pOJ160, appear blue on these plates. Colonies that contain a plasmid with an insert, such as E. coli K12 RR1ΔM15/pOJ313, are white. Several apramycin-resistant, white colonies were selected and then screened by restriction enzyme analysis of their plasmid DNA. Unwanted vectors were differentiated from plasmids pOJ313 and pOJ313A by digestion with restriction enzymes such as AhaIII and XbaI. These sites are present in portions of plasmid pOJ171 derived from plasmid pKC462A but are completely absent in the Streptomyces thermotolerans DNA insert portion of pOJ171, which contains the carE gene. Plasmid DNA was obtained from the E. coli K12 RR1ΔM15/pOJ313 transformants in accordance with the procedure for isolating plasmid pOJ160 DNA, described above. The plasmid pOJ313 DNA can be used to transform Streptomyces, as described in Examples 5 and 6, below.
PAC Construction of Plasmids pOJ230 and pOJ231The polylinker in the lacZα-fragment-encoding DNA of plasmid pOJ160 contains a BamHI restriction enzyme cleavage site. Plasmid pOJ160 was digested with restriction enzyme BamHI, treated with alkaline phosphatase, and ligated with the ∼2.4 kb, carE-containing, BamHI restriction fragment of plasmid pOJ159. This ligation produced plasmids pOJ230 (FIG. 5) and pOJ231. The ligated DNA was used to transform E. coli and transformants analyzed as described in Example 3.
PAC Transformation of Streptomyces ambofaciens With Vectors Containing the carE GeneThe following solutions are referred to throughout the Examples and are presented here for clarity.
| ______________________________________ |
| Ingredient Amount |
| ______________________________________ |
| 1. P Media (∼100 ml): |
| Sucrose 10.3 g |
| K2 SO4 0.025 g |
| Trace element solution 0.2 ml |
| (see #3) |
| MgCl2.6H2 O 0.203 g |
| Water 80 ml |
| After autoclaving add: |
| KH2 PO4 (0.5%) 1 ml |
| CaCl2.2H2 O (3.68%) |
| 10 ml |
| (N-tris-(hydroxymethyl)- 10 ml |
| methyl-2-aminoethane |
| sulphonic acid), |
| "TES" buffer, 0.25 M, |
| pH = 7.2 |
| 2. Trace element solution (∼1 L): |
| ZnCl2 40 mg |
| FeCl3.6H2 O 200 mg |
| CuCl2.2H2 O 10 mg |
| MnCl2.4H2 O 10 mg |
| Na2 B4 O7.10H2 O |
| 10 mg |
| (NH4)6 Mo7 O24.4H2 O |
| 10 mg |
| H2 O 1 L |
| 3. R2 Regeneration Media (∼1 L): |
| Sucrose 103 g |
| K2 SO4 0.25 g |
| Trace element solution 2 ml |
| MgCl2.6H2 O 10.12 g |
| glucose 10 g |
| L-asparagine.1H2 O 2.0 g |
| casamino acids 0.1 g |
| Agar 22 g |
| Water to 700 ml |
| *Yeast extract 5 g |
| The pH is adjusted to pH = 7.2 before |
| autoclaving. |
| After autoclaving, add: |
| KH2 PO4 (0.05 g/100 ml) |
| 100 ml |
| CaCl2 (2.22 g/100 ml) 100 ml |
| TES Buffer (5.73 g/100 ml, 100 ml |
| pH = 7.2) |
| 4. Soft Nutrient Agar (SNA, ∼1 L): |
| Difco Bacto Nutrient Broth 8 g |
| Agar 5 g |
| 5. R2YE medium is R2 medium with 20 ml of |
| 25% yeast extract added per liter. |
| 6. Yeast Extract-Malt Extract (YEME, ∼1 L): |
| Yeast extract 3 g |
| Peptone 5 g |
| Malt extract 3 g |
| Glucose 10 g |
| 7. YEME + 34% Sucrose Liquid Complete Media |
| is YEME with 340 g/L of sucrose. |
| 8. YMX Media (∼1 L): |
| Yeast extract 3 g |
| Malt extract 3 g |
| Glucose 2 g |
| Agar 20 g |
| 9. YMX Agar is 0.3% yeast extract, 0.3% |
| malt extract, 0.2% dextrose, and 2.0% agar. |
| 10. CSI Media (∼1 L): |
| Soybean meal 15 g |
| Casein 1 g |
| Cerelose 25 g |
| Blackstrap molasses 3 g |
| CaCO3 2.5 g |
| Czapek Mineral Stock 2 ml |
| Water (deionized) 1 L |
| pH adjusted to 7.2 prior to |
| sterilization |
| 11. Czapek's Mineral Mix (∼1 L): |
| KCl 100 g |
| MgSO4.7H2 O 100 g |
| Deionized Water 900 ml |
| FeSO4.7H2 O (2 g) was dissolved in 100 ml |
| deionized water containing 2 ml of concentrated |
| HCl. This solution was added to the above |
| KCl/MgSO4.7H2 O solution to complete |
| preparation of the Czapek's Mineral Mix. |
| 12. Bennett's Agar (∼1 L): |
| Deionized H2 O 1000 ml |
| Potato Dextrin 10 g |
| N-Z Amine A 2 g |
| Gibco bactoagar 15 g |
| Gibco beef extract 2 g |
| Yeast extract 1 g |
| Czapek's mineral stock 2 ml |
| 13. AS1 (∼1 L) |
| Yeast Extract 1 g |
| L-alanine 0.2 g |
| L-arginine (free base) 0.2 g |
| L-asparagine 0.5 g |
| Soluble starch 5 g |
| NaCl 2.5 g |
| Na 2 SO4 10 g |
| Meer Agar 20 g |
| H2 O to 1 L |
| Adjust pH to 7.5 with NaOH |
| ______________________________________ |
| *For use in Streptomyces ambofaciens transformations only. |
Plasmids pOJ159, pOJ171, pOJ230, pOJ231, and pOJ313 were individually used to transform Streptomyces ambofaciens in substantial accordance with the procedure set forth below.
Streptomyces ambofaciens was plated on Bennett's agar and incubated at 30°C for about 72 hours. A spore scraping was removed from the plate and used to inoculate 10 ml of TSB. The culture was incubated in an air-shaker incubator at 30°C for ∼30 hours. This culture was homogenized; then, 3 ml of the culture were used to inoculate 17 ml of TSB containing 0.4% glycine. The culture was incubated in an air-shaker incubator at 30°C for about ∼24 hours. This culture was again homogenized; then, 3 ml of the culture were used to inoculate 17 ml of TSB containing 0.4% glycine. The culture was incubated at 30°C for about 16 hours. The culture was again homogenized; then, the mycelial fragments were harvested and washed with a 10.3% sucrose solution. The mycelial fragments were resuspended in 20 ml of P media containing 1 mg/ml lysozyme, and the resulting solution was incubated at room temperature for about one to one-and-one-half hours. During this protoplasting step, the cells were pipetted up and down to disperse clumps. The protoplasts were collected and washed two times with P medium. The protoplasts were then suspended in 10 ml of P medium. This process usually generates about 2 to 5×107 protoplasts per 200 μl of solution.
Approximately 150 μl of the protoplast solution were used per transformation. About 1 μg of the transforming DNA, in 10 μl of either ligation or TE buffer, was added to the protoplasts; then, about 100 μl of 50% polyethylene glycol 1000 (Sigma) in P media were added to and mixed with the protoplasts. The cell-DNA mixture was vortexed and then plated onto R2 medium (Example 3A3); each plate was inoculated with about 0.1 ml of cells mixed with ∼3 ml of R2-modified soft agar (103 g sucrose, 0.5% agar 10.12 g MgCl2, 2.22 g CaCl2, and 5.72 g TES at pH =7.2 per liter). The plates were incubated at 30°C overnight (∼16 hours) and then overlaid with ∼3 ml of R2-modified soft agar containing enough apramycin or thiostrepton to give a final concentration, after diffusion, of 25 μg/ml. The plates were then incubated for about four days at 30°C, when colonies became visible to the unaided eye.
Streptomyces ambofaciens transformants containing plasmids pOJ159, pOJ171, pOJ230, pOJ231, or pOJ313 were patched from the R2-agar regeneration plates to plates containing AS1 and 25 μg/ml apramycin and incubated at 30° for 2-3 days until the colonies were ∼5 millimeters in diameter. The colonies were then plugged and the plugs transferred, using a sterile transfer tube (Spectrum Medical Industrial, Inc., Los Angeles, Calif. 90054) to trypticase soy agar (TSA) plates, which had been previously overlayed with soft-agar nutrient broth (Difco Laboratories, Detroit, Mich. 48232) containing Micrococcus luteus X160 (ATCC 9341). The plates were incubated at 37°C for 16-24 hours. Micrococcus luteus (ATCC 9341) is sensitive to spiramycin and isovaleryl spiramycin and resistant to apramycin. Consequently, this M. luteus strain cannot grow around a plug which contains Streptomyces that are producing spiramycin or isovaleryl spiramycin.
Streptomyces ambofaciens transformants were patched onto AS1 containing 25 μl of apramycin and 0.5 mg/ml of L-leucine (the substrate for acylase). A plug assay was performed to determine whether the colonies had begun to produce spiramycin. After two to three more days, plugs were removed for bioautography, described in part D of this example.
The plate-plug assay was used to indicate production of antibiotic by Streptomyces ambofaciens, which normally produces spiramycin in AS1 medium. The production of spiramycin results in zones of inhibition of Micrococcus luteus growth around the plug. Several additional days of incubation at 30°C were required for conversion of the endogenously-produced spiramycin to isovaleryl spiramycin in the cultures harboring a carE expression vector. S. ambofaciens transformed with plasmid pOJ159 were maintained on R2 and AS1 media containing 25 μg/ml of thiostrepton, but because M. luteus is sensitive to thiostrepton, antibiotic production could not be measured as above. S. ambofaciens/pOJ159 cultures were incubated about six days before plugs were used for bioautography. Thiostrepton was included as a standard on chromatography plates when S. ambofaciens/pOJ159 and S. lividans TK23/pOJ159 cultures were assayed by bioautography.
Several plugs were prepared from the plates containing the Streptomyces ambofaciens and S. lividans transformants of the invention. These plugs were placed onto a thin-layer chromatography plate (Merck, P.O. Box 2000, Rahway, N.J. 07065, pre-coated silica gel #60 F-254) next to samples of spiramycin and isovaleryl spiramycin standards. The plugs were left on the plate for a time sufficient for diffusion to occur; then, the plate was subjected to ascending liquid chromatography in 95:5:5 ethylacetate:diethylamine:methanol. The developed chromatograms were dried thoroughly in a fume hood for at least two hours. The chromatograms were then placed face down on Micrococcus luteus X160-seeded TSA plates for ∼15 minutes. The chromatograms were removed from the plates, and the plates were incubated at 37° for 16-24 hours.
The chromatograms for the plugs prepared from the Streptomyces ambofaciens transformants produced zones of inhibition resulting from substances on the chromatogram that comigrated with the isovaleryl spiramycin standard.
PAC Transformation and Culture of Streptomyces lividansStreptomyces lividans TK23 (NRRL 15826) was plated on R2 agar, and the plates were incubated at 30°C for 16 hours. A plug of cells was taken from the plate and used to inoculate 10 ml of TSS-glycine (12% sucrose and 0.5% glycine in TSB). This culture was incubated at 30° C. for ∼65 hours with aeration. The culture was then homogenized, sonicated, pelleted with centrifugation, and washed with 10 ml of P media. The cell pellet was resuspended in P media containing 2 mg/ml lysozyme, incubated at 4°C for 15 minutes, mixed by inversion, and then incubated at 4°C for 30 minutes. The resulting protoplasts were washed twice in P media and then resuspended in 10 ml of P media. For each sample of transforming DNA (∼5 μg), 200 μl of protoplasts were added to the DNA, and then, 0.5 ml of 20% polyethylene glycol 1000 in P media was added to the cell-DNA mixture. The cells were then plated in 200 μl aliquots using ∼3 ml of R2-modified overlays (103 g sucrose, 10.12 g MgCl2, 2.22 g CaCl2, and 5.73 g TES at pH=7.2 per liter). The plates were incubated at 30°C
The plates were incubated at 30°C overnight (∼16 hours) and then overlaid with ∼3 ml of R2-modified agar (103 g sucrose, 10.12 g MgCl2, 2.22 g CaCl2, and 5.72 g TES at pH=7.2 per liter) containing enough thiostrepton or apramycin to give a final concentration, after diffusion, of 25 μg/ml. The plates were then incubated for about four days at 30°C, when colonies became visible to the naked eye.
The transformants were patched onto AS1 media supplemented with apramycin or thiostrepton (25 μg/ml), 0.5 μg/ml leucine, and 100 μg/ml of spiramycin and allowed to grow several days, until sporulation and pigmentation indicated well-established growth. Plugs were then removed for bioautography, performed as described in the previous Example.
PAC Construction of Plasmid pOJ235The coding sequence of the carE gene can be reconstructed by first isolating the 5' end of the coding sequence from plasmid pOJ231 (or plasmid pOJ230) on an ∼700 bp PstI-BamHI restriction fragment. This fragment is purified and then digested with restriction enzyme SfaNI. The ∼100 bp SfaNI-PstI restriction that results from this digestion is then isolated, purified, and ligated with NdeI-PstI-digested plasmid pUC19 and the following linker: ##STR2## The ligation produces plasmid pOJ232, which then serves as a source for an ∼130 bp NdeI-PstI restriction fragment that encodes the 5' end of the coding sequence of the carE gene.
The remainder of the carE coding sequence can be obtained on an ∼1.7 kb BamHI-PstI restriction fragment of plasmid pOJ231 (or plasmid pOJ230). This ∼1.7 kb BamHI-PstI restriction fragment of plasmid pOJ231 is ligated with the ∼130 bp NdeI-PstI restriction fragment of plasmid pOJ232 and the ∼5.8 kb NdeI-BamHI restriction fragment of plasmid pCZR336 to yield plasmid pOJ235. Plasmid pOJ235 drives expression of the carE gene product at temperatures above ∼37°C (at which temperature the cI857 λpL repressor is inactivated) in E. coli.
The ∼5.8 kb NdeI-BamHI fragment from pCZR336 contains DNA sequences coding for the λpL promoter, a translation activating sequence, the cI857 repressor, a plasmid origin of replication, and a tetracycline resistance-conferring gene. Plasmid pCZR336 also contains a coding sequence for human growth hormone. The DNA sequences contained in the ∼5.8 kb NdeI-BamHI fragment of plasmid pCZR336 can be constructed as described below.
Most of the DNA in the ∼5.8 kb NdeI-BamHI restriction fragment of plasmid pCZR336 can be isolated from plasmid pCZR111 on an ∼5.75 kb XbaI-BamHI restriction fragment. A restriction site and function map of plasmid pCZR111 is presented in FIG. 7 of the accompanying drawings. Plasmid pCZR111 can be obtained from E. coli K12 RV308/pCZR111, available from the NRRL under accession number NRRL B-18249. Plasmid pCZR111 confers resistance to 10 μg/ml tetracycline and lacks a ClaI restriction site.
Plasmid pCZR111 is digested with XbaI and BamHI enzymes, and the large XbaI-BamHI fragment is purified from agarose. This XbaI-BamHI restriction fragment of plasmid pCZR111 is ligated together with a double stranded DNA fragment to yield the ∼5.8 kb NdeI-BamHI restriction fragment of plasmid pCZR336. The double stranded DNA fragment has the following sequence: ##STR3##
Those skilled in the art recognize that the fewer DNA fragments required for a ligation, the greater the likelihood that the desired plasmid will be produced by the ligation. Thus, plasmid pOJ235 could be constructed by using the 5.75 kb XbaI-BamHI fragment of plasmid pCZR111 and the DNA fragment described above in place of the single ∼5.8 kb NdeI-BamHI fragment in the construction protocol for plasmid pOJ235, but yields of the desired plasmid would probably be lower. Plasmid pOJ235 drives expression of the carE gene product in E. coli.
Schoner, Brigitte E., Epp, Janet K.
| Patent | Priority | Assignee | Title |
| 5240849, | May 24 1988 | ECO ANIMAL HEALTH LIMITED | DNA coding for enzyme capable of acylating the 4"-position of macrolide antibiotic |
| 6265202, | Jun 26 1998 | Regents of the University of Minnesota | DNA encoding methymycin and pikromycin |
| 6600029, | Dec 19 1995 | Regents of the University of Minnesota | Metabolic engineering of polyhydroxyalkanoate monomer synthases |
| Patent | Priority | Assignee | Title |
| 4935340, | Jun 07 1985 | Eli Lilly and Company | Method of isolating antibiotic biosynthetic genes |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| May 12 1988 | EPP, JANET K | ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285 A CORP OF INDIANA | ASSIGNMENT OF ASSIGNORS INTEREST | 005673 | /0740 | |
| May 12 1988 | SCHONER, BRIGITTE E | ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285 A CORP OF INDIANA | ASSIGNMENT OF ASSIGNORS INTEREST | 005673 | /0740 | |
| May 13 1988 | Eli Lilly and Company | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Mar 01 1995 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Apr 07 1995 | ASPN: Payor Number Assigned. |
| Jun 22 1999 | REM: Maintenance Fee Reminder Mailed. |
| Nov 28 1999 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Nov 26 1994 | 4 years fee payment window open |
| May 26 1995 | 6 months grace period start (w surcharge) |
| Nov 26 1995 | patent expiry (for year 4) |
| Nov 26 1997 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Nov 26 1998 | 8 years fee payment window open |
| May 26 1999 | 6 months grace period start (w surcharge) |
| Nov 26 1999 | patent expiry (for year 8) |
| Nov 26 2001 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Nov 26 2002 | 12 years fee payment window open |
| May 26 2003 | 6 months grace period start (w surcharge) |
| Nov 26 2003 | patent expiry (for year 12) |
| Nov 26 2005 | 2 years to revive unintentionally abandoned end. (for year 12) |